ABOUT THE SPEAKER
Bill Doyle - Engineer
With his company Novocure, Bill Doyle works to bring breakthrough medical technologies to doctors and patients.

Why you should listen

Bill Doyle is the executive chair of Novocure, a company commercializing a new therapeutic modality for solid tumors using low-intensity electric fields. Recently, Novocure received FDA approval for its first indication, recurrent Glioblastoma Multiforme (GBM), the most virulent form of brain cancer; it is now conducting additional clinical trials.

In 2002, Doyle co-founded medical device venture firm WFD Ventures, which provides financing and business-building expertise to medical device companies with the potential to make a major impact on patient care, working with entrepreneurs, doctors and scientists to improve medical outcomes and maximize the potential of their innovations.

A graduate of MIT, Doyle stablished the MIT FIRST Scholarship for FIRST Robotics Competition participants admitted to MIT.

Watch Jay Walker's onstage Q&A with Bill Doyle >>

More profile about the speaker
Bill Doyle | Speaker | TED.com
TEDMED 2011

Bill Doyle: Treating cancer with electric fields

Filmed:
664,368 views

Surgery, chemotherapy and radiation are the best-known methods for treating cancer. At TEDMED, Bill Doyle presents a new approach, called Tumor Treating Fields, which uses electric fields to interrupt cancer cell division. Still in its infancy -- and approved for only certain types of cancer -- the treatment comes with one big benefit: quality of life.
- Engineer
With his company Novocure, Bill Doyle works to bring breakthrough medical technologies to doctors and patients. Full bio

Double-click the English transcript below to play the video.

00:15
Everybody in our society's life is touched by cancer --
0
0
3000
00:18
if not personally,
1
3000
2000
00:20
then through a loved one, a family member,
2
5000
3000
00:23
colleague, friend.
3
8000
2000
00:25
And once our lives are touched by cancer,
4
10000
3000
00:28
we quickly learn
5
13000
2000
00:30
that there are basically
6
15000
2000
00:32
three weapons, or three tools, that are available
7
17000
3000
00:35
to fight the disease:
8
20000
3000
00:38
surgery, radiation and chemotherapy.
9
23000
3000
00:41
And once we get involved
10
26000
3000
00:44
in the therapeutic decisions,
11
29000
3000
00:47
again either personally
12
32000
2000
00:49
or with our loved ones and family members,
13
34000
3000
00:52
we also very quickly learn
14
37000
3000
00:55
the benefits, the trade-offs and the limitations
15
40000
3000
00:58
of these tools.
16
43000
2000
01:00
I'm very thankful to Jay and to Mark
17
45000
2000
01:02
and the TEDMED team
18
47000
2000
01:04
for inviting me today
19
49000
2000
01:06
to describe a fourth tool, a new tool,
20
51000
3000
01:09
that we call Tumor Treating Fields.
21
54000
3000
01:12
Tumor Treating Fields
22
57000
2000
01:14
were invented by Dr. Yoram Palti,
23
59000
3000
01:17
professor emeritus at the Technion in Israel.
24
62000
3000
01:20
And they use low-intensity
25
65000
2000
01:22
electric fields
26
67000
2000
01:24
to fight cancer.
27
69000
2000
01:26
To understand how Tumor Treating Fields work,
28
71000
3000
01:29
we first need to understand
29
74000
2000
01:31
what are electric fields.
30
76000
2000
01:33
Let me first address
31
78000
3000
01:36
a few popular misconceptions.
32
81000
3000
01:39
First of all, electric fields
33
84000
2000
01:41
are not an electric current
34
86000
2000
01:43
that is coursing through the tissue.
35
88000
3000
01:46
Electric fields
36
91000
2000
01:48
are not ionizing radiation,
37
93000
2000
01:50
like X-rays or proton beams,
38
95000
2000
01:52
that bombard tissue
39
97000
2000
01:54
to disrupt DNA.
40
99000
2000
01:56
And electric fields
41
101000
2000
01:58
are not magnetism.
42
103000
2000
02:00
What electric fields are
43
105000
2000
02:02
are a field of forces.
44
107000
3000
02:05
And these forces
45
110000
2000
02:07
act on, attract, bodies
46
112000
3000
02:10
that have an electrical charge.
47
115000
3000
02:13
The best way to visualize an electric field
48
118000
2000
02:15
is to think of gravity.
49
120000
2000
02:17
Gravity is also a field of forces
50
122000
3000
02:20
that act on masses.
51
125000
2000
02:22
We can all picture astronauts in space.
52
127000
3000
02:25
They float freely in three dimensions
53
130000
2000
02:27
without any forces acting on them.
54
132000
2000
02:29
But as that space shuttle
55
134000
3000
02:32
returns to Earth,
56
137000
2000
02:34
and as the astronauts enter the Earth's gravitational field,
57
139000
3000
02:37
they begin to see the effects of gravity.
58
142000
3000
02:40
They begin to be attracted towards Earth.
59
145000
2000
02:42
And as they land,
60
147000
2000
02:44
they're fully aligned in the gravitational field.
61
149000
2000
02:46
We're, of course, all stuck in the Earth's gravitational field right now.
62
151000
3000
02:49
That's why you're all in your chairs.
63
154000
3000
02:52
And that's why we have to use our muscle energy
64
157000
2000
02:54
to stand up, to walk around
65
159000
2000
02:56
and to lift things.
66
161000
3000
02:59
In cancer,
67
164000
2000
03:01
cells rapidly divide
68
166000
2000
03:03
and lead to uncontrolled tumor growth.
69
168000
3000
03:06
We can think of a cell
70
171000
3000
03:09
from an electrical perspective
71
174000
2000
03:11
as if it's a mini space station.
72
176000
3000
03:14
And in that space station
73
179000
2000
03:16
we have the genetic material, the chromosomes,
74
181000
3000
03:19
within a nucleus.
75
184000
2000
03:21
And out in the cytoplasmic soup
76
186000
2000
03:23
we have special proteins
77
188000
2000
03:25
that are required for cell division
78
190000
2000
03:27
that float freely in this soup
79
192000
2000
03:29
in three dimensions.
80
194000
2000
03:31
Importantly, those special proteins
81
196000
3000
03:34
are among the most highly charged objects
82
199000
3000
03:37
in our body.
83
202000
2000
03:39
As cell division begins
84
204000
2000
03:41
the nucleus disintegrates,
85
206000
2000
03:43
the chromosomes line up
86
208000
2000
03:45
in the middle of the cell
87
210000
2000
03:47
and those special proteins
88
212000
2000
03:49
undergo a three-dimensional sequence
89
214000
4000
03:53
whereby they attach
90
218000
2000
03:55
and they literally click into place end-on-end
91
220000
3000
03:58
to form chains.
92
223000
2000
04:00
These chains
93
225000
2000
04:02
then progress and attach
94
227000
2000
04:04
to the genetic material
95
229000
3000
04:07
and pull the genetic material
96
232000
2000
04:09
from one cell into two cells.
97
234000
2000
04:11
And this is exactly how
98
236000
2000
04:13
one cancer cell becomes two cancer cells,
99
238000
2000
04:15
two cancer cells become four cancer cells,
100
240000
2000
04:17
and we have ultimately
101
242000
2000
04:19
uncontrolled tumor growth.
102
244000
3000
04:22
Tumor Treating Fields
103
247000
3000
04:25
use externally placed transducers
104
250000
4000
04:29
attached to a field generator
105
254000
3000
04:32
to create an artificial electric field
106
257000
4000
04:36
on that space station.
107
261000
3000
04:39
And when that cellular space station
108
264000
3000
04:42
is within the electric field,
109
267000
2000
04:44
it acts on those highly charged proteins
110
269000
4000
04:48
and aligns them.
111
273000
2000
04:50
And it prevents them from forming those chains,
112
275000
3000
04:53
those mitotic spindles,
113
278000
2000
04:55
that are necessary to pull the genetic material
114
280000
3000
04:58
into the daughter cells.
115
283000
2000
05:00
What we see is that the cells will attempt to divide
116
285000
3000
05:03
for several hours.
117
288000
2000
05:05
And they will either enter into
118
290000
3000
05:08
this so-called cellular suicide,
119
293000
2000
05:10
programmed cell death,
120
295000
2000
05:12
or they will form unhealthy daughter cells
121
297000
3000
05:15
and enter into apoptosis
122
300000
3000
05:18
once they have divided.
123
303000
2000
05:20
And we can observe this.
124
305000
2000
05:22
What I'm going to show you next
125
307000
2000
05:24
are two in vitro experiments.
126
309000
2000
05:26
This is cultures, identical cultures,
127
311000
3000
05:29
of cervical cancer cells.
128
314000
2000
05:31
And we've stained these cultures
129
316000
2000
05:33
with a green florescent dye
130
318000
2000
05:35
so that we can look at these proteins
131
320000
3000
05:38
that form these chains.
132
323000
2000
05:40
The first clip shows
133
325000
2000
05:42
a normal cell division
134
327000
3000
05:45
without the Tumor Treating Fields.
135
330000
3000
05:48
What we see
136
333000
2000
05:50
are, first of all, a very active culture,
137
335000
2000
05:52
a lot of divisions,
138
337000
2000
05:54
and then very clear nuclei
139
339000
2000
05:56
once the cells have separated.
140
341000
2000
05:58
And we can see them dividing throughout.
141
343000
2000
06:00
When we apply the fields --
142
345000
2000
06:02
again, in the identical time-scale
143
347000
2000
06:04
to the identical culture --
144
349000
2000
06:06
you're going to see something different.
145
351000
2000
06:08
The cells round up for division,
146
353000
2000
06:10
but they're very static in that position.
147
355000
3000
06:13
We'll see two cells
148
358000
2000
06:15
in the upper part of the screen
149
360000
5000
06:20
attempting to divide.
150
365000
2000
06:22
The one within the circle manages.
151
367000
2000
06:24
But see how much of the protein
152
369000
2000
06:26
is still throughout the nucleus,
153
371000
2000
06:28
even in the dividing cell.
154
373000
2000
06:30
The one up there can't divide at all.
155
375000
2000
06:32
And then this bubbling, this membrane bubbling,
156
377000
3000
06:35
is the hallmark
157
380000
2000
06:37
of apoptosis in this cell.
158
382000
3000
06:40
Formation of healthy mitotic spindles
159
385000
4000
06:44
is necessary for division
160
389000
3000
06:47
in all cell types.
161
392000
2000
06:49
We've applied Tumor Treating Fields
162
394000
2000
06:51
to over 20 different cancers in the lab,
163
396000
3000
06:54
and we see this effect
164
399000
2000
06:56
in all of them.
165
401000
3000
06:59
Now importantly,
166
404000
2000
07:01
these Tumor Treating Fields have no effect
167
406000
3000
07:04
on normal undividing cells.
168
409000
2000
07:06
10 years ago,
169
411000
2000
07:08
Dr. Palti founded a company called Novocure
170
413000
3000
07:11
to develop his discovery
171
416000
3000
07:14
into a practical therapy for patients.
172
419000
3000
07:17
In that time, Novocure's developed two systems --
173
422000
4000
07:21
one system for cancers in the head
174
426000
3000
07:24
and another system for cancers in the trunk of the body.
175
429000
3000
07:27
The first cancer that we have focused on
176
432000
3000
07:30
is the deadly brain cancer, GBM.
177
435000
3000
07:33
GBM affects about 10,000 people
178
438000
3000
07:36
in the U.S. each year.
179
441000
3000
07:39
It's a death sentence.
180
444000
2000
07:41
The expected five year survival
181
446000
2000
07:43
is less than five percent.
182
448000
2000
07:45
And the typical patient
183
450000
2000
07:47
with optimal therapy
184
452000
2000
07:49
survives just a little over a year,
185
454000
3000
07:52
and only about seven months
186
457000
2000
07:54
from the time that the cancer is first treated
187
459000
3000
07:57
and then comes back and starts growing again.
188
462000
3000
08:02
Novocure conducted
189
467000
2000
08:04
its first phase three randomized trial
190
469000
2000
08:06
in patients with recurrent GBM.
191
471000
2000
08:08
So these are patients
192
473000
2000
08:10
who had received surgery,
193
475000
4000
08:14
high dose radiation to the head
194
479000
2000
08:16
and first-line chemotherapy,
195
481000
2000
08:18
and that had failed and their tumors had grown back.
196
483000
3000
08:21
We divided the patients into two groups.
197
486000
3000
08:24
The first group received second-line chemotherapy,
198
489000
3000
08:27
which is expected to double the life expectancy,
199
492000
3000
08:30
versus no treatment at all.
200
495000
2000
08:32
And then the second group
201
497000
2000
08:34
received only Tumor Treating Field therapy.
202
499000
3000
08:37
What we saw in that trial
203
502000
2000
08:39
is that that the life expectancies of both groups --
204
504000
3000
08:42
so the chemotherapy treated group
205
507000
2000
08:44
and the Tumor Treating Field group --
206
509000
2000
08:46
was the same.
207
511000
2000
08:48
But importantly,
208
513000
2000
08:50
the Tumor Treating Field group
209
515000
3000
08:53
suffered none of the side effects
210
518000
3000
08:56
typical of chemotherapy patients.
211
521000
3000
08:59
They had no pain,
212
524000
2000
09:01
suffered none of the infections.
213
526000
3000
09:04
They had no nausea, diarrhea,
214
529000
3000
09:07
constipation, fatigue
215
532000
3000
09:10
that would be expected.
216
535000
2000
09:12
Based on this trial,
217
537000
2000
09:14
in April of this year,
218
539000
2000
09:16
the FDA approved Tumor Treating Fields
219
541000
3000
09:19
for the treatment of patients
220
544000
2000
09:21
with recurrent GBM.
221
546000
3000
09:24
Importantly, it was the first time ever
222
549000
3000
09:27
that the FDA included
223
552000
2000
09:29
in their approval of an oncology treatment
224
554000
3000
09:32
a quality of life claim.
225
557000
2000
09:36
So I'm going to show you now
226
561000
3000
09:39
one of the patients
227
564000
2000
09:41
from this trial.
228
566000
3000
09:44
Robert Dill-Bundi
229
569000
2000
09:46
is a famous Swiss cycling champion.
230
571000
2000
09:48
He won the gold medal in Moscow
231
573000
2000
09:50
in the 4,000 meter pursuit.
232
575000
3000
09:53
And five years ago,
233
578000
3000
09:56
Robert was diagnosed with GBM.
234
581000
3000
09:59
He received the standard treatments.
235
584000
2000
10:01
He received surgery.
236
586000
3000
10:04
He received high dose radiation to the head.
237
589000
3000
10:07
And he received first-line chemotherapy.
238
592000
3000
10:10
A year after this treatment --
239
595000
2000
10:12
in fact, this is his baseline MRI.
240
597000
3000
10:15
You can see that the black regions
241
600000
3000
10:18
in the upper right quadrant
242
603000
2000
10:20
are the areas where he had surgery.
243
605000
2000
10:22
And a year after that treatment,
244
607000
2000
10:24
his tumor grew back with a vengeance.
245
609000
3000
10:27
That cloudy white mass that you see
246
612000
3000
10:30
is the recurrence of the tumor.
247
615000
3000
10:33
At this point, he was told by his doctors
248
618000
3000
10:36
that he had about 3 months to live.
249
621000
3000
10:39
He entered our trial.
250
624000
2000
10:41
And here we can see him getting the therapy.
251
626000
3000
10:44
First of all, these electrodes are noninvasive.
252
629000
3000
10:47
They're attached to the skin
253
632000
2000
10:49
in the area of the tumor.
254
634000
2000
10:51
Here you can see
255
636000
2000
10:53
that a technician is placing them on there much like bandages.
256
638000
3000
10:56
The patients learn to do this themselves
257
641000
3000
10:59
And then the patients
258
644000
3000
11:02
can undergo all the activities of their daily life.
259
647000
3000
11:05
There's none of the tiredness.
260
650000
2000
11:07
There's none of what is called the "chemo head."
261
652000
3000
11:10
There's no sensation.
262
655000
2000
11:12
It doesn't interfere
263
657000
2000
11:14
with computers or electrical equipment.
264
659000
3000
11:17
And the therapy is delivered continuously
265
662000
2000
11:19
at home,
266
664000
2000
11:21
without having to go into the hospital
267
666000
2000
11:23
either periodically or continually.
268
668000
3000
11:26
These are Robert's MRIs,
269
671000
3000
11:29
again, under only TTField treatment.
270
674000
3000
11:32
This is a therapy that takes time to work.
271
677000
3000
11:35
It's a medical device;
272
680000
2000
11:37
it works when it's on.
273
682000
2000
11:39
But what we can see is, by month six,
274
684000
2000
11:41
the tumor has responded
275
686000
3000
11:44
and it's begun to melt away.
276
689000
3000
11:47
It's still there.
277
692000
2000
11:49
By month 12,
278
694000
2000
11:51
we could argue whether
279
696000
2000
11:53
there's a little bit of material around the edges,
280
698000
2000
11:55
but it's essentially completely gone.
281
700000
3000
11:58
It's now five years
282
703000
2000
12:00
since Robert's diagnosis,
283
705000
2000
12:02
and he's alive,
284
707000
3000
12:05
but importantly, he's healthy
285
710000
2000
12:07
and he's at work.
286
712000
2000
12:09
I'm going to let him, in this very short clip,
287
714000
2000
12:11
describe his impressions of the therapy
288
716000
2000
12:13
in his own words.
289
718000
2000
12:15
(Video) Robert Dill-Bundi: My quality of life,
290
720000
2000
12:17
I rate what I have today
291
722000
2000
12:19
a bit different than what most people would assume.
292
724000
4000
12:23
I am the happiest, the happiest person in the world.
293
728000
5000
12:28
And every single morning I appreciate life.
294
733000
4000
12:32
Every night I fall asleep very well,
295
737000
3000
12:35
and I am, I repeat,
296
740000
3000
12:38
the happiest man in the world,
297
743000
2000
12:40
and I'm thankful I am alive.
298
745000
3000
12:45
BD: Novocure's also working on lung cancer
299
750000
3000
12:48
as the second target.
300
753000
2000
12:50
We've run a phase two trial
301
755000
2000
12:52
in Switzerland
302
757000
2000
12:54
on, again, recurrent patients --
303
759000
2000
12:56
patients who have received standard therapy
304
761000
3000
12:59
and whose cancer has come back.
305
764000
3000
13:02
I'm going to show you another clip
306
767000
2000
13:04
of a woman named Lydia.
307
769000
2000
13:06
Lydia's a 66 year-old farmer
308
771000
2000
13:08
in Switzerland.
309
773000
2000
13:10
She was diagnosed with lung cancer
310
775000
2000
13:12
five years ago.
311
777000
2000
13:14
She underwent four different regimes of chemotherapy
312
779000
3000
13:17
over two years,
313
782000
2000
13:19
none of which had an effect.
314
784000
2000
13:21
Her cancer continued to grow.
315
786000
2000
13:23
Three years ago,
316
788000
2000
13:25
she entered the Novocure lung cancer trial.
317
790000
4000
13:29
You can see, in her case,
318
794000
2000
13:31
she's wearing her transducer arrays,
319
796000
2000
13:33
one of the front of her chest, one on the back,
320
798000
3000
13:36
and then the second pair side-to-side over the liver.
321
801000
3000
13:39
You can see the Tumor Treating Field field generator,
322
804000
3000
13:42
but importantly you can also see that she is living her life.
323
807000
3000
13:45
She is managing her farm.
324
810000
2000
13:47
She's interacting with her kids and her grand kids.
325
812000
3000
13:50
And when we talked to her,
326
815000
3000
13:53
she said that when she was undergoing chemotherapy,
327
818000
2000
13:55
she had to go to the hospital every month for her infusions.
328
820000
3000
13:58
Her whole family suffered
329
823000
2000
14:00
as her side effect profile came and went.
330
825000
2000
14:02
Now she can run
331
827000
2000
14:04
all of the activities of her farm.
332
829000
3000
14:07
It's only the beginning.
333
832000
2000
14:09
(Applause)
334
834000
7000
14:16
In the lab, we've observed tremendous synergies
335
841000
4000
14:20
between chemotherapy and Tumor Treating Fields.
336
845000
3000
14:23
There's research underway now at Harvard Medical School
337
848000
3000
14:26
to pick the optimum pairs
338
851000
2000
14:28
to maximize that benefit.
339
853000
2000
14:30
We also believe that Tumor Treating Fields will work with radiation
340
855000
3000
14:33
and interrupt the self-repair mechanisms that we have.
341
858000
4000
14:37
There's now a new research project underway
342
862000
2000
14:39
at the Karolinska in Sweden
343
864000
2000
14:41
to prove that hypothesis.
344
866000
2000
14:43
We have more trials planned
345
868000
2000
14:45
for lung cancer,
346
870000
2000
14:47
pancreatic cancer, ovarian cancer
347
872000
2000
14:49
and breast cancer.
348
874000
2000
14:51
And I firmly believe
349
876000
2000
14:53
that in the next 10 years
350
878000
2000
14:55
Tumor Treating Fields
351
880000
2000
14:57
will be a weapon available to doctors and patients
352
882000
3000
15:00
for all of these most-difficult-to-treat solid tumors.
353
885000
5000
15:06
I'm also very hopeful
354
891000
2000
15:08
that in the next decades,
355
893000
2000
15:10
we will make big strides
356
895000
2000
15:12
on reducing that death rate
357
897000
3000
15:15
that has been so challenging in this disease.
358
900000
3000
15:18
Thank you.
359
903000
2000
15:20
(Applause)
360
905000
9000

▲Back to top

ABOUT THE SPEAKER
Bill Doyle - Engineer
With his company Novocure, Bill Doyle works to bring breakthrough medical technologies to doctors and patients.

Why you should listen

Bill Doyle is the executive chair of Novocure, a company commercializing a new therapeutic modality for solid tumors using low-intensity electric fields. Recently, Novocure received FDA approval for its first indication, recurrent Glioblastoma Multiforme (GBM), the most virulent form of brain cancer; it is now conducting additional clinical trials.

In 2002, Doyle co-founded medical device venture firm WFD Ventures, which provides financing and business-building expertise to medical device companies with the potential to make a major impact on patient care, working with entrepreneurs, doctors and scientists to improve medical outcomes and maximize the potential of their innovations.

A graduate of MIT, Doyle stablished the MIT FIRST Scholarship for FIRST Robotics Competition participants admitted to MIT.

Watch Jay Walker's onstage Q&A with Bill Doyle >>

More profile about the speaker
Bill Doyle | Speaker | TED.com